Literature DB >> 23238467

Potential role of licofelone, minocycline and their combination against chronic fatigue stress induced behavioral, biochemical and mitochondrial alterations in mice.

Anil Kumar1, Aditi Vashist, Puneet Kumar, Harikesh Kalonia, Jitendriya Mishra.   

Abstract

BACKGROUND: Chronic fatigue stress (CFS) is a common complaint among general population. Persistent and debilitating fatigue severely impairs daily functioning and is usually accompanied by combination of several physical and psychiatric problems. It is now well established fact that oxidative stress and neuroinflammation are involved in the pathophysiology of chronic fatigue and related disorders. Targeting both COX (cyclooxygenase) and 5-LOX (lipoxygenase) pathways have been proposed to be involved in neuroprotective effect.
METHODS: In the present study, mice were put on the running wheel apparatus for 6 min test session daily for 21 days, what produced fatigue like condition. The locomotor activity and anxiety like behavior were measured on 0, 8(th), 15(th) and 22(nd) day. The brains were isolated on 22(nd) day immediately after the behavioral assessments for the estimation of oxidative stress parameters and mitochondrial enzyme complexes activity.
RESULTS: Pre-treatment with licofelone (2.5, 5 and 10 mg/kg, po) and minocycline (50 and 100 mg/kg, po) for 21 days, significantly attenuated fatigue like behavior as compared to the control (rotating wheel activity test session, RWATS) group. Further, licofelone (5 and 10 mg/kg, po) and minocycline (50 and 100 mg/kg, po) drug treatments for 21 days significantly attenuated behavioral alterations, oxidative damage and restored mitochondrial enzyme complex activities (I, II, III and IV) as compared to control, whereas combination of licofelone (5 mg/kg) with minocycline (50 mg/kg) significantly potentiated their protective effect which was significant as compared to their effect per se.
CONCLUSION: The present study highlights the therapeutic potential of licofelone, minocycline and their combination against CFS in mice.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23238467     DOI: 10.1016/s1734-1140(12)70907-6

Source DB:  PubMed          Journal:  Pharmacol Rep        ISSN: 1734-1140            Impact factor:   3.024


  6 in total

1.  Minocycline protects against oxidative damage and alters energy metabolism parameters in the brain of rats subjected to chronic mild stress.

Authors:  Gislaine Z Réus; Helena M Abelaira; Amanda L Maciel; Maria Augusta B Dos Santos; Anelise S Carlessi; Amanda V Steckert; Gabriela K Ferreira; Samira D De Prá; Emilio L Streck; Danielle S Macêdo; João Quevedo
Journal:  Metab Brain Dis       Date:  2014-08-13       Impact factor: 3.584

2.  Neuroprotective mechanism of losartan and its interaction with nimesulide against chronic fatigue stress.

Authors:  Anil Kumar; Barinder Singh; Jitendriya Mishra; Sangeeta Pilkhwal Sah; Raghavender Pottabathini
Journal:  Inflammopharmacology       Date:  2015-06-30       Impact factor: 4.473

3.  A pilot study of minocycline for the prevention of paclitaxel-associated neuropathy: ACCRU study RU221408I.

Authors:  Deirdre R Pachman; Travis Dockter; Patricia J Zekan; Briant Fruth; Kathryn J Ruddy; Lauren E Ta; Jacqueline M Lafky; Todor Dentchev; Nguyet Anh Le-Lindqwister; William M Sikov; Nathan Staff; Andreas S Beutler; Charles L Loprinzi
Journal:  Support Care Cancer       Date:  2017-05-27       Impact factor: 3.603

4.  Effect of licofelone--a dual COX/5-LOX inhibitor in intracerebroventricular streptozotocin-induced behavioral and biochemical abnormalities in rats.

Authors:  Ashok Kumar; Sorabh Sharma; Ashwani Prashar; Rahul Deshmukh
Journal:  J Mol Neurosci       Date:  2014-09-10       Impact factor: 3.444

5.  SCORHE: a novel and practical approach to video monitoring of laboratory mice housed in vivarium cage racks.

Authors:  Ghadi H Salem; John U Dennis; Jonathan Krynitsky; Marcial Garmendia-Cedillos; Kanchan Swaroop; James D Malley; Sinisa Pajevic; Liron Abuhatzira; Michael Bustin; Jean-Pierre Gillet; Michael M Gottesman; James B Mitchell; Thomas J Pohida
Journal:  Behav Res Methods       Date:  2015-03

Review 6.  Microglia and Autism Spectrum Disorder: Overview of Current Evidence and Novel Immunomodulatory Treatment Options.

Authors:  Jung Won Kim; Ji Yeon Hong; Seung Min Bae
Journal:  Clin Psychopharmacol Neurosci       Date:  2018-08-31       Impact factor: 2.582

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.